VREfm is one of the most problematic pathogens in hospitals, especially in immunodeficient patients, and constitutes an emerging local and global health crisis.
The recipient of the NIAID grant — Michael Rybak, PharmD, professor of pharmacy practice in WSU’s Eugene Applebaum College of Pharmacy and Health Sciences and adjunct professor of medicine in WSU’s School of Medicine — will study how various dosing regimens of daptomycin, a lipopeptide antibiotic, affect VREfm.
“Daptomycin has demonstrated bactericidal activity against VREfm in vitro, but the development of resistance during therapy has threatened its viability for future use,” said Dr. Rybak. “Our research will evaluate several dosing regimens of DAP against VREfm strains in the DAP ‘susceptible’ minimum inhibitory concentration range with genetically proven proclivity for DAP resistance development.”
His research team will also assess several beta-lactam antibiotics in combination with DAP against VREfm.
“Dr. Rybak is superbly qualified and well-positioned to conduct this important work,” said Brian Crabtree, PharmD, chair of the Department of Pharmacy Practice at WSU.
More articles on VRE:
Executive briefing: How 2 hospitals used pulsed xenon UV disinfection to slash HAI rates
Combination of chemicals, UV light stops infection transmission best, study finds
Does implementing a risk-managed approach reduce VRE?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
